Order |
Header |
Start Date |
End Date |
Comments |
Size |
Archive
|
1 |
Covid19 |
2020-12-06 06:48 |
2021-10-12 14:54 |
5 |
2166 |
Talk:Molnupiravir/Archive 1
|
2 |
IUPAC name |
2021-10-01 15:54 |
2021-10-02 21:36 |
2 |
603 |
Talk:Molnupiravir/Archive 1
|
3 |
Seasons |
2021-10-12 14:49 |
2021-10-12 14:49 |
1 |
775 |
Talk:Molnupiravir/Archive 1
|
4 |
"See also" section |
2021-10-04 12:06 |
2021-10-04 17:17 |
3 |
1154 |
Talk:Molnupiravir/Archive 1
|
5 |
Registry number |
2021-10-13 00:40 |
2021-10-13 11:12 |
2 |
979 |
Talk:Molnupiravir/Archive 1
|
6 |
Cancer and birth defects claims |
2021-10-15 19:12 |
2021-10-18 23:36 |
3 |
1306 |
Talk:Molnupiravir/Archive 1
|
7 |
Etymology of the name |
2021-11-04 13:24 |
2021-11-04 16:08 |
3 |
678 |
Talk:Molnupiravir/Archive 1
|
8 |
Marketing and expected sales |
2021-11-09 00:32 |
2021-11-09 07:10 |
2 |
1346 |
Talk:Molnupiravir/Archive 1
|
9 |
Concerns raised over mutation of SARS-CoV-2 |
2021-11-09 13:49 |
2022-01-05 14:19 |
25 |
24191 |
Talk:Molnupiravir/Archive 1
|
10 |
French Regulators Refuse Authorization and NIH recommends only use as a last resort |
2022-02-08 14:26 |
2022-02-08 14:26 |
1 |
5117 |
Talk:Molnupiravir/Archive 1
|
11 |
See also (for early covid-19 treatment): Pfizer Paxlovid. |
2021-11-14 21:58 |
2021-11-15 11:57 |
3 |
1126 |
Talk:Molnupiravir/Archive 1
|
12 |
Phase III results on NEJM: not WP:MEDRS? |
2021-12-27 15:12 |
2021-12-29 16:19 |
7 |
4796 |
Talk:Molnupiravir/Archive 1
|